ATLANTA, August 14, 2026, 04:16 EDT – Accelerant stock surged 44% after Thoma Bravo announced a $20.25 per share deal, with the spread holding at 4%.
- Thoma Bravo proposed to acquire Accelerant at $20.25 per share in cash, reflecting a 49% premium.
- Thursday’s premarket quote of $19.47 resulted in an initial gross deal spread of 4.0%.
- The planned closing period runs until the end of the first half of 2027.
Shares of Accelerant Holdings NYSE:ARX surged close to 44% as Thoma Bravo announced a deal to acquire the specialty-insurance marketplace. The proposed all-cash offer of $20.25 per share gives the company an equity value nearing $4.4 billion. Still, a premarket price of $19.47 on Thursday left about a 4.0% gap to the offer level.
The gap has become the main focus for investors. Factors like closing schedules, regulatory consent and safeguards for deals outweigh earnings growth. On Friday, U.S. premarket trading started early, but the main cash session stayed shut.
The stated premium puts the offer $6.66 higher than the August 12 closing price. However, the figure stands $0.75 under Accelerant’s initial public offering price of $21. The company went public in July 2025.
| Reference point | Price | Difference versus offer |
|---|---|---|
| Implied August 12 close | $13.59 | +$6.66 / +49.0% |
| Thursday premarket quote | $19.47 | +$0.78 / +4.0% |
| Thoma Bravo cash offer | $20.25 | — |
| July 2025 IPO price | $21.00 | -$0.75 / -3.6% |
Accelerant reported around 218.2 million Class A and Class B shares last quarter, translating to an implied equity value of $4.42 billion. With shares priced at $19.47, the valuation was about $4.25 billion, showing a difference of close to $170 million.
The timing significantly alters the return. The table below shows the fixed $0.78 spread annualised from August 14. These are initial calculations, not predictions, and do not factor in taxes or trading expenses.
| Illustrative closing date | Days from August 14 | Gross spread | Annualised gross return |
|---|---|---|---|
| December 31, 2026 | 139 | 4.0% | 10.9% |
| March 31, 2027 | 229 | 4.0% | 6.5% |
| June 30, 2027 | 320 | 4.0% | 4.6% |
The merger pact introduces a 6% yearly ticking fee in the event that outstanding insurance approvals postpone the deal’s completion. This fee is not applied from the announcement date. Calculated at the offer price, the 6% represents roughly $0.10 per share each month after it takes effect.
Backing for the deal appears unusually centralized. Altamont Capital Partners holds approximately 82% of Accelerant’s voting power and has committed to endorsing the deal. Altamont, along with the founders, will keep a stake. The agreement was unanimously endorsed by a special committee.
| Deal factor | Verified term | Investor relevance |
|---|---|---|
| Voting support | Altamont controls roughly 82% | Limits uncertainty around shareholder votes |
| Board process | Independent special committee with unanimous endorsement | Bolsters process legitimacy |
| Rollover | Equity retained by Altamont and founders | Keeps ongoing ownership stake |
| Expected close | Set for first half of 2027 | Defines timeframe for spread |
| Delayed approvals | Annual ticking fee of 6% when in force | Mitigates qualified delay effects |
RBC analyst Rowland Mayor described the deal as “a good outcome,” pointing to market fluctuations and a valuation gap. Thoma Bravo principal Matt LoSardo stated that Accelerant had developed “something rare in specialty insurance.” Reuters
Analyst targets set before the deal varied and have mostly been overtaken. The $20.25 bid exceeded a number of recent forecasts, though it remained below TD Cowen’s $30 target. This range reflected the uncertain valuation environment ahead of the offer.
| Firm | Recommendation | Price target | Latest cited date |
|---|---|---|---|
| TD Cowen | Buy | $30 | March 26, 2026 |
| BMO Capital | Buy | $17 | June 16, 2026 |
| Piper Sandler | Buy | $19 | May 26, 2026 |
| Morgan Stanley | Hold | $16 | May 21, 2026 |
The purchaser is taking on risks that public markets had already factored in. These involved Accelerant’s intricate ownership structure and its connections to related insurer Hadron. Shares dropped to $9 at their lowest, after previously reaching almost $30.
Risks: Approval could be held up or denied by insurance regulators. The deal could also fall through due to financing issues, contract troubles or business disruptions. The 6% ticking fee only applies in certain cases of delayed approval and does not fully offset potential downside.
Investors await complete details on the merger filing, including all conditions and termination clauses. The $20.25 level remains the cap for now, and the spread reflects market confidence. Timing is now crucial.
Related articles: Stock Market
